Начало・Списък с акции・Glaukos Corp

Glaukos Corp

Затворен

СекторЗдравеопазване

184.3 -2.71

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

183.83

Максимум

189.31

Ключови измерители
By Trading Economics
Приходи	1.4M -18M
Продажби	35M 186M
EPS	-0.14
Марж на печалбата	-9.901
Служители	1,094
EBITDA	-11M -16M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+0.17% upside

Дивиденти
By Acuity
Следващи печалби	28.10.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.8B 11B
Предишно отваряне	187.01
Предишно затваряне	184.3

Настроения в новините

By Acuity

50%

163 / 340 Класиране в Healthcare

Glaukos Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.08.2026 г., 19:46 ч. UTC

Glaukos Corp. shares are lower today, reaching a session low amid broader market declines following a surprise drop in U.S. retail sales for July.

13.08.2026 г., 19:22 ч. UTC

Glaukos Corp. shares are higher today amid unusually high trading volume. The stock remains significantly above its 20-day moving average.

12.08.2026 г., 19:16 ч. UTC

Glaukos Corp shares are higher today, supported by overall strength in U.S. stocks and positive quarterly results from AI sector companies.

10.08.2026 г., 20:06 ч. UTC

Glaukos Corp shares are higher today, following a broader market trend since Friday. Earlier, the stock reached a session high before pulling back.

7.08.2026 г., 20:02 ч. UTC

Glaukos Corp shares are rising in Friday's session, supported by unusually high trading volume and a steady upward trend since Thursday's close.

4.08.2026 г., 19:36 ч. UTC

Glaukos Corp shares are lower today, impacted by declines in the Health Care Equipment sub-sector. The stock pulled back after reaching an earlier high.

3.08.2026 г., 20:06 ч. UTC

Glaukos Corp shares are higher amid positive market sentiment, with the S&P 500 and Nasdaq 100 also gaining. The stock remains above its 20-day moving average.

31.07.2026 г., 19:45 ч. UTC

News

Glaukos shares are lower today despite H.C. Wainwright raising the price target to $195 from $168. Trading volume has been unusually high.

30.07.2026 г., 21:31 ч. UTC

News

Glaukos Corp shares are lower in after-market trading, tracking declines in the Health Care Equipment sector. UBS raised its price target to $172.

29.07.2026 г., 21:22 ч. UTC

Social Media

News

Glaukos Corp reported record net sales of $185.6 million in Q2 2026, raising its full-year revenue guidance to $680 million to $700 million. Shares are higher in after-market trading.

28.07.2026 г., 17:46 ч. UTC

News

Glaukos Corp shares are lower after UBS initiated coverage with a Neutral rating, overshadowing Stifel's Buy rating and $175 price target.

27.07.2026 г., 19:16 ч. UTC

Glaukos Corp shares are lower today, despite an initial gain. Broader market trends are affected by a significant drop in oil prices.

24.07.2026 г., 19:56 ч. UTC

Glaukos Corp. shares are trading higher today, maintaining a cumulative gain since Thursday and remaining above their 20-day moving average.

21.07.2026 г., 17:41 ч. UTC

Glaukos Corp shares are lower today amid a decline in the Health Care Equipment sub-sector, reversing the recent trend of higher daily closes.

Сравнение с други в отрасъла

Ценова промяна

Glaukos Corp Прогноза

Ценова цел

By TipRanks

0.17% нагоре

12-месечна прогноза

Среден 189.77 USD 0.17%

Висок 225 USD

Нисък 153 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Glaukos Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Glaukos Corp през последните 3 месеца.

Настроение

By Acuity

163 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.